

# Steven C Wallis

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3541216/publications.pdf>

Version: 2024-02-01

138  
papers

5,519  
citations

94269

37  
h-index

88477

70  
g-index

139  
all docs

139  
docs citations

139  
times ranked

4064  
citing authors

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 1  | DALI: Defining Antibiotic Levels in Intensive Care Unit Patients: Are Current $\beta$ -Lactam Antibiotic Doses Sufficient for Critically Ill Patients?. <i>Clinical Infectious Diseases</i> , 2014, 58, 1072-1083.   | 2.9 | 843       |
| 2  | Beta-Lactam Infusion in Severe Sepsis (BLISS): a prospective, two-centre, open-labelled randomised controlled trial of continuous versus intermittent beta-lactam infusion in critically ill patients with severe sepsis. <i>Intensive Care Medicine</i> , 2016, 42, 1535-1545.  | 3.9 | 244       |
| 3  | Sequestration of drugs in the circuit may lead to therapeutic failure during extracorporeal membrane oxygenation. <i>Critical Care</i> , 2012, 16, R194.   | 2.5 | 233       |
| 4  | Protein-bound drugs are prone to sequestration in the extracorporeal membrane oxygenation circuit: results from an ex vivo study. <i>Critical Care</i> , 2015, 19, 164.  | 2.5 | 181       |
| 5  | Analysis of 12 beta-lactam antibiotics in human plasma by HPLC with ultraviolet detection. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2010, 878, 2039-2043.   | 1.2 | 172       |
| 6  | Meropenem and piperacillin/tazobactam prescribing in critically ill patients: does augmented renal clearance affect pharmacokinetic/pharmacodynamic target attainment when extended infusions are used?. <i>Critical Care</i> , 2013, 17, R84.   | 2.5 | 166       |
| 7  | Risk factors for target non-attainment during empirical treatment with $\beta$ -lactam antibiotics in critically ill patients. <i>Intensive Care Medicine</i> , 2014, 40, 1340-1351.   | 3.9 | 147       |
| 8  | Is prolonged infusion of piperacillin/tazobactam and meropenem in critically ill patients associated with improved pharmacokinetic/pharmacodynamic and patient outcomes? An observation from the Defining Antibiotic Levels in Intensive care unit patients (DALI) cohort. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 196-207. | 1.3 | 129       |
| 9  | Low Plasma Cefepime Levels in Critically Ill Septic Patients: Pharmacokinetic Modeling Indicates Improved Troughs with Revised Dosing. <i>Antimicrobial Agents and Chemotherapy</i> , 1999, 43, 2559-2561.   | 1.4 | 115       |
| 10 | Copper(II) complexes of the fluoroquinolone antimicrobial ciprofloxacin. Synthesis, X-ray structural characterization, and potentiometric study. <i>Journal of Inorganic Biochemistry</i> , 1996, 62, 1-16.  | 1.5 | 112       |
| 11 | Are standard doses of piperacillin sufficient for critically ill patients with augmented creatinine clearance?. <i>Critical Care</i> , 2015, 19, 28.   | 2.5 | 111       |
| 12 | Pharmacokinetic variability and exposures of fluconazole, anidulafungin, and caspofungin in intensive care unit patients: Data from multinational Defining Antibiotic Levels in Intensive care unit (DALI) patients Study. <i>Critical Care</i> , 2015, 19, 33.  | 2.5 | 108       |
| 13 | Flucloxacillin dosing in critically ill patients with hypoalbuminaemia: special emphasis on unbound pharmacokinetics. <i>Journal of Antimicrobial Chemotherapy</i> , 2010, 65, 1771-1778.  | 1.3 | 102       |
| 14 | Assays for therapeutic drug monitoring of $\beta$ -lactam antibiotics: A structured review. <i>International Journal of Antimicrobial Agents</i> , 2015, 46, 367-375.  | 1.1 | 95        |
| 15 | ASAP ECMO: Antibiotic, Sedative and Analgesic Pharmacokinetics during Extracorporeal Membrane Oxygenation: a multi-centre study to optimise drug therapy during ECMO. <i>BMC Anesthesiology</i> , 2012, 12, 29.  | 0.7 | 90        |
| 16 | The combined effects of extracorporeal membrane oxygenation and renal replacement therapy on meropenem pharmacokinetics: a matched cohort study. <i>Critical Care</i> , 2014, 18, 565.   | 2.5 | 87        |
| 17 | Does contemporary vancomycin dosing achieve therapeutic targets in a heterogeneous clinical cohort of critically ill patients? Data from the multinational DALI study. <i>Critical Care</i> , 2014, 18, R99.   | 2.5 | 87        |
| 18 | The Effect of Renal Replacement Therapy and Antibiotic Dose on Antibiotic Concentrations in Critically Ill Patients: Data From the Multinational Sampling Antibiotics in Renal Replacement Therapy Study. <i>Clinical Infectious Diseases</i> , 2021, 72, 1369-1378.   | 2.9 | 85        |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 19 | Cefepime Versus Cefpirome: The Importance of Creatinine Clearance. <i>Anesthesia and Analgesia</i> , 2003, 97, 1149-1154.  | 1.1 | 81        |
| 20 | Co-administration of sub-antinociceptive doses of oxycodone and morphine produces marked antinociceptive synergy with reduced CNS side-effects in rats. <i>Pain</i> , 2000, 84, 421-428.   | 2.0 | 75        |
| 21 | Low cefpirome levels during twice daily dosing in critically ill septic patients: pharmacokinetic modelling calls for more frequent dosing. <i>Intensive Care Medicine</i> , 2001, 27, 363-370.  | 3.9 | 69        |
| 22 | Plasma and Tissue Pharmacokinetics of Cefazolin in Patients Undergoing Elective and Semielective Abdominal Aortic Aneurysm Open Repair Surgery. <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 5238-5242.  | 1.4 | 68        |
| 23 | Meropenem Dosing in Critically Ill Patients with Sepsis Receiving High-Volume Continuous Venovenous Hemofiltration. <i>Antimicrobial Agents and Chemotherapy</i> , 2010, 54, 2974-2978.  | 1.4 | 67        |
| 24 | Can physicochemical properties of antimicrobials be used to predict their pharmacokinetics during extracorporeal membrane oxygenation? Illustrative data from ovine models. <i>Critical Care</i> , 2015, 19, 437.  | 2.5 | 67        |
| 25 | Determining the mechanisms underlying augmented renal drug clearance in the critically ill: use of exogenous marker compounds. <i>Critical Care</i> , 2014, 18, 657.   | 2.5 | 64        |
| 26 | Plasma and target-site subcutaneous tissue population pharmacokinetics and dosing simulations of cefazolin in post-trauma critically ill patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 1495-1502.   | 1.3 | 60        |
| 27 | Population Pharmacokinetics of Fosfomycin in Critically Ill Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 6471-6476.  | 1.4 | 59        |
| 28 | Interaction of Norfloxacin with Divalent and Trivalent Pharmaceutical Cations. In Vitro Complexation and in Vivo Pharmacokinetic Studies in the Dog. <i>Journal of Pharmaceutical Sciences</i> , 1996, 85, 803-809.  | 1.6 | 56        |
| 29 | Population Pharmacokinetics of Piperacillin in Nonobese, Obese, and Morbidly Obese Critically Ill Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .   | 1.4 | 54        |
| 30 | Cerebrospinal Fluid Penetration of High Doses of Intravenous Ciprofloxacin in Meningitis. <i>Clinical Infectious Diseases</i> , 2000, 31, 1131-1133.   | 2.9 | 51        |
| 31 | Pharmacokinetics of meropenem in critically ill patients receiving continuous venovenous haemofiltration: A randomised controlled trial of continuous infusion versus intermittent bolus administration. <i>International Journal of Antimicrobial Agents</i> , 2015, 45, 41-45. | 1.1 | 50        |
| 32 | Pharmacokinetics of ciprofloxacin in ICU patients on continuous veno-venous haemodiafiltration. <i>Intensive Care Medicine</i> , 2001, 27, 665-672.  | 3.9 | 47        |
| 33 | DALI: Defining Antibiotic Levels in Intensive care unit patients: a multi-centre point of prevalence study to determine whether contemporary antibiotic dosing for critically ill patients is therapeutic. <i>BMC Infectious Diseases</i> , 2012, 12, 152.                       | 1.3 | 47        |
| 34 | Synthesis and X-ray structural characterization of an iron(III) complex of the fluoroquinolone antimicrobial ciprofloxacin, [Fe(CIP)(NTA)]3 $\cdot$ 5H <sub>2</sub> O (NTA $\hat{=}$ Nitilotriacetato). <i>Polyhedron</i> , 1995, 14, 2835-2840.                                 | 1.0 | 45        |
| 35 | Quantitative bioanalytical validation of fosfomycin in human whole blood with volumetric absorptive microsampling. <i>Bioanalysis</i> , 2015, 7, 2585-2595.  | 0.6 | 45        |
| 36 | Altered antibiotic pharmacokinetics during extracorporeal membrane oxygenation: cause for concern?. <i>Journal of Antimicrobial Chemotherapy</i> , 2013, 68, 726-727.  | 1.3 | 42        |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 37 | Maximally effective dosing regimens of meropenem in patients with septic shock. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 191-198.   | 1.3 | 40        |
| 38 | Effect of Obesity on the Population Pharmacokinetics of Meropenem in Critically Ill Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 4577-4584.   | 1.4 | 38        |
| 39 | Effect of Obesity on the Population Pharmacokinetics of Fluconazole in Critically Ill Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 6550-6557.   | 1.4 | 38        |
| 40 | Effect of different renal function on antibacterial effects of piperacillin against <i>Pseudomonas aeruginosa</i> evaluated via the hollow-fibre infection model and mechanism-based modelling. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 2509-2520.                 | 1.3 | 38        |
| 41 | Population Pharmacokinetics of Unbound Ceftolozane and Tazobactam in Critically Ill Patients without Renal Dysfunction. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .  | 1.4 | 35        |
| 42 | Substantial Impact of Altered Pharmacokinetics in Critically Ill Patients on the Antibacterial Effects of Meropenem Evaluated via the Dynamic Hollow-Fiber Infection Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .  | 1.4 | 34        |
| 43 | Caspofungin Population Pharmacokinetics in Critically Ill Patients Undergoing Continuous Veno-Venous Haemofiltration or Haemodiafiltration. <i>Clinical Pharmacokinetics</i> , 2017, 56, 1057-1068.   | 1.6 | 32        |
| 44 | Optimising meropenem dosing in critically ill Australian Indigenous patients with severe sepsis. <i>International Journal of Antimicrobial Agents</i> , 2016, 48, 542-546.  | 1.1 | 30        |
| 45 | Doripenem population pharmacokinetics and dosing requirements for critically ill patients receiving continuous venovenous haemodiafiltration. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 2508-2516.   | 1.3 | 29        |
| 46 | Effect of time on recovery of plasma microsamples for the quantitative determination of vancomycin. <i>Bioanalysis</i> , 2016, 8, 2235-2242.  | 0.6 | 29        |
| 47 | Influence of Renal Replacement Modalities on Amikacin Population Pharmacokinetics in Critically Ill Patients on Continuous Renal Replacement Therapy. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 4901-4909.   | 1.4 | 29        |
| 48 | Pharmacokinetics of piperacillin in critically ill patients receiving continuous venovenous haemofiltration: A randomised controlled trial of continuous infusion versus intermittent bolus administration. <i>International Journal of Antimicrobial Agents</i> , 2015, 46, 39-44. | 1.1 | 28        |
| 49 | A simple LC-MS/MS method using HILIC chromatography for the determination of fosfomycin in plasma and urine: Application to a pilot pharmacokinetic study in humans. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2015, 105, 39-45.                                   | 1.4 | 28        |
| 50 | <i>Ex Vivo</i> Characterization of Effects of Renal Replacement Therapy Modalities and Settings on Pharmacokinetics of Meropenem and Vaborbactam. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .  | 1.4 | 27        |
| 51 | Rapid and economical high-performance liquid chromatographic method for the determination of norfloxacin in serum using a microparticulate C18 guard cartridge. <i>Biomedical Applications</i> , 1995, 674, 306-309.  | 1.7 | 25        |
| 52 | Clinical application of microsampling versus conventional sampling techniques in the quantitative bioanalysis of antibiotics: a systematic review. <i>Bioanalysis</i> , 2018, 10, 407-423.  | 0.6 | 25        |
| 53 | Pharmacokinetics of meropenem and piperacillin in critically ill patients with indwelling surgical drains. <i>International Journal of Antimicrobial Agents</i> , 2013, 42, 90-93.  | 1.1 | 24        |
| 54 | A validated method for the quantification of fosfomycin on dried plasma spots by HPLC-MS/MS: Application to a pilot pharmacokinetic study in humans. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2015, 115, 509-514.   | 1.4 | 23        |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 55 | A UHPLC-MS/MS method for the simultaneous determination of piperacillin and tazobactam in plasma (total and unbound), urine and renal replacement therapy effluent. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2018, 148, 324-333.  | 1.4 | 23        |
| 56 | Spectroscopic and ligand-field analysis of the spin-orbit interaction between the $1E_g$ and $3T_2g$ states in bis(1,4,7-triazacyclononane)nickel(II). <i>Journal of the Chemical Society Dalton Transactions</i> , 1992, , 2971-2976.  | 1.1 | 22        |
| 57 | Total and unbound ceftriaxone pharmacokinetics in critically ill Australian Indigenous patients with severe sepsis. <i>International Journal of Antimicrobial Agents</i> , 2016, 48, 748-752.   | 1.1 | 22        |
| 58 | Determination of Cefalothin and Cefazolin in Human Plasma, Urine and Peritoneal Dialysate by UHPLC-MS/MS: application to a pilot pharmacokinetic study in humans. <i>Biomedical Chromatography</i> , 2016, 30, 872-879.   | 0.8 | 22        |
| 59 | Population pharmacokinetics of total and unbound concentrations of intravenous posaconazole in adult critically ill patients. <i>Critical Care</i> , 2019, 23, 205.   | 2.5 | 22        |
| 60 | Are interstitial fluid concentrations of meropenem equivalent to plasma concentrations in critically ill patients receiving continuous renal replacement therapy?. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 528-533.  | 1.3 | 21        |
| 61 | Optimization and Evaluation of Piperacillin-Tobramycin Combination Dosage Regimens against <i>Pseudomonas aeruginosa</i> for Patients with Altered Pharmacokinetics via the Hollow-Fiber Infection Model and Mechanism-Based Modeling. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, . | 1.4 | 21        |
| 62 | Meropenem-Tobramycin Combination Regimens Combat Carbapenem-Resistant <i>Pseudomonas aeruginosa</i> in the Hollow-Fiber Infection Model Simulating Augmented Renal Clearance in Critically Ill Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 64, .                               | 1.4 | 21        |
| 63 | A Population Pharmacokinetic Model-Guided Evaluation of Ceftolozane-Tazobactam Dosing in Critically Ill Patients Undergoing Continuous Venovenous Hemodiafiltration. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 64, .   | 1.4 | 21        |
| 64 | Is there a role for microsampling in antibiotic pharmacokinetic studies?. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2016, 12, 601-614.  | 1.5 | 20        |
| 65 | Impact of renal replacement modalities on the clearance of piperacillin-tazobactam administered via continuous infusion in critically ill patients. <i>International Journal of Antimicrobial Agents</i> , 2017, 50, 227-231.   | 1.1 | 20        |
| 66 | Pharmacokinetics of a novel dosing regimen of oral melatonin in critically ill patients. <i>Clinical Chemistry and Laboratory Medicine</i> , 2016, 54, 467-72.  | 1.4 | 19        |
| 67 | Development of simulated and ovine models of extracorporeal life support to improve understanding of circuit-host interactions. <i>Critical Care and Resuscitation: Journal of the Australasian Academy of Critical Care Medicine</i> , 2012, 14, 105-11.   | 0.0 | 19        |
| 68 | Pharmacokinetics of Intraperitoneal Gentamicin in Peritoneal Dialysis Patients with Peritonitis (GIPD) Tj ETQq0 0 0 rBT /Overlock 10 Tf   | 2.2 | 18        |
| 69 | Defining optimal dosing of ciprofloxacin in patients with septic shock. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 1662-1669.   | 1.3 | 18        |
| 70 | An LC-MS/MS method to determine vancomycin in plasma (total and unbound), urine and renal replacement therapy effluent. <i>Bioanalysis</i> , 2017, 9, 911-924.  | 0.6 | 17        |
| 71 | Pharmacokinetics of Intravenous Posaconazole in Critically Ill Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .   | 1.4 | 17        |
| 72 | Lung Pharmacokinetics of Tobramycin by Intravenous and Nebulized Dosing in a Mechanically Ventilated Healthy Ovine Model. <i>Anesthesiology</i> , 2019, 131, 344-355.   | 1.3 | 17        |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 73 | Comparison of equal doses of continuous venovenous haemofiltration and haemodiafiltration on ciprofloxacin population pharmacokinetics in critically ill patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 1643-1650.                                   | 1.3 | 16        |
| 74 | Population Pharmacokinetics of Levetiracetam in Patients with Traumatic Brain Injury and Subarachnoid Hemorrhage Exhibiting Augmented Renal Clearance. <i>Clinical Pharmacokinetics</i> , 2021, 60, 655-664.   | 1.6 | 16        |
| 75 | Evaluation of Meropenem+Ciprofloxacin Combination Dosage Regimens for the Pharmacokinetics of Critically Ill Patients With Augmented Renal Clearance. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 109, 1104-1115.  | 2.3 | 16        |
| 76 | Cerebrospinal Fluid Penetration of Ceftolozane-Tazobactam in Critically Ill Patients with an Indwelling External Ventricular Drain. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 65, .   | 1.4 | 15        |
| 77 | Ceftolozane+tazobactam in an elastomeric infusion device for ambulatory care: an in vitro stability study. <i>European Journal of Hospital Pharmacy</i> , 2020, 27, e84-e86.   | 0.5 | 15        |
| 78 | Pharmacokinetics of Piperacillin in Critically Ill Australian Indigenous Patients with Severe Sepsis. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 7402-7406.  | 1.4 | 14        |
| 79 | Sampling Antibiotics in Renal Replacement Therapy (SMARRT): an observational pharmacokinetic study in critically ill patients. <i>BMC Infectious Diseases</i> , 2016, 16, 103.   | 1.3 | 14        |
| 80 | Conventional Pig as Animal Model for Human Renal Drug Excretion Processes: Unravelling the Porcine Renal Function by Use of a Cocktail of Exogenous Markers. <i>Frontiers in Pharmacology</i> , 2020, 11, 883.   | 1.6 | 14        |
| 81 | Prophylactic Cefazolin Dosing in Women With Body Mass Index $\geq 35 \text{ kg m}^{-2}$ Undergoing Cesarean Delivery: A Pharmacokinetic Study of Plasma and Interstitial Fluid. <i>Anesthesia and Analgesia</i> , 2020, 131, 199-207.                                    | 1.1 | 14        |
| 82 | Can We Use an Ex Vivo Continuous Hemofiltration Model to Describe the Adsorption and Elimination of Meropenem and Piperacillin?. <i>International Journal of Artificial Organs</i> , 2015, 38, 419-424.  | 0.7 | 13        |
| 83 | Intravascular administration sets are accurate and in appropriate condition after 7 days of continuous use: an in vitro study. <i>Journal of Advanced Nursing</i> , 2002, 37, 330-337.   | 1.5 | 12        |
| 84 | Analysis of capillary microsamples obtained from a skin-prick to measure vancomycin concentrations as a valid alternative to conventional sampling: A bridging study. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2019, 169, 288-292.                     | 1.4 | 12        |
| 85 | Pharmacodynamic evaluation of intermittent versus extended and continuous infusions of piperacillin/tazobactam in a hollow-fibre infection model against <i>Klebsiella pneumoniae</i> . <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 2633-2640.              | 1.3 | 12        |
| 86 | Population pharmacokinetics of cefepime in critically ill patients receiving extracorporeal membrane oxygenation (an ASAP ECMO study). <i>International Journal of Antimicrobial Agents</i> , 2021, 58, 106466.  | 1.1 | 12        |
| 87 | Stability of Antibiotics for Intraperitoneal Administration in Extraneal 7.5% Icodextrin Peritoneal Dialysis Bags (Stab Study). <i>Peritoneal Dialysis International</i> , 2016, 36, 421-426.  | 1.1 | 11        |
| 88 | Population Pharmacokinetics of Doripenem in Critically Ill Patients with Sepsis in a Malaysian Intensive Care Unit. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 206-214.  | 1.4 | 11        |
| 89 | A validated LC-MSMS method for the simultaneous quantification of meropenem and vaborbactam in human plasma and renal replacement therapy effluent and its application to a pharmacokinetic study. <i>Analytical and Bioanalytical Chemistry</i> , 2019, 411, 7831-7840. | 1.9 | 11        |
| 90 | An Integrated Dialysis Pharmacometric (IDP) Model to Evaluate the Pharmacokinetics in Patients Undergoing Renal Replacement Therapy. <i>Pharmaceutical Research</i> , 2020, 37, 96.  | 1.7 | 10        |



| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 91  | An UHPLC-MS/MS method for the simultaneous determination of ampicillin and sulbactam in human plasma and urine. <i>Bioanalysis</i> , 2015, 7, 2311-2319.   | 0.6 | 9         |
| 92  | Evidence of clinical response and stability of Ceftolozane/Tazobactam used to treat a carbapenem-resistant <i>Pseudomonas Aeruginosa</i> lung abscess on an outpatient antimicrobial program. <i>International Journal of Antimicrobial Agents</i> , 2018, 51, 941-942.                | 1.1 | 9         |
| 93  | Population Pharmacokinetics of Piperacillin and Tazobactam in Critically Ill Patients Receiving Extracorporeal Membrane Oxygenation: an ASAP ECMO Study. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, e0143821.  | 1.4 | 9         |
| 94  | Accuracy of pleural fluid pH and PCO <sub>2</sub> measurement in a blood gas analyser. Analysis of bias and precision. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 1999, 59, 619-626.   | 0.6 | 8         |
| 95  | Population Pharmacokinetics and Dosing Simulations of Ceftriaxone in Critically Ill Patients Receiving Extracorporeal Membrane Oxygenation (An ASAP ECMO Study). <i>Clinical Pharmacokinetics</i> , 2022, 61, 847-856.   | 1.6 | 8         |
| 96  | Multicenter Population Pharmacokinetic Study of Unbound Ceftriaxone in Critically Ill Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2022, 66, e0218921.   | 1.4 | 8         |
| 97  | Pharmacokinetics of Intraperitoneal Cefalothin and Cefazolin in Patients Being Treated for Peritoneal Dialysis-Associated Peritonitis. <i>Peritoneal Dialysis International</i> , 2016, 36, 415-420.   | 1.1 | 7         |
| 98  | A research pathway for the study of the delivery and disposition of nebulised antibiotics: an incremental approach from in vitro to large animal models. <i>Intensive Care Medicine Experimental</i> , 2018, 6, 17.  | 0.9 | 7         |
| 99  | A pharmacokinetic case study of intravenous posaconazole in a critically ill patient with hypoalbuminaemia receiving continuous venovenous haemodiafiltration. <i>International Journal of Antimicrobial Agents</i> , 2018, 52, 506-509.   | 1.1 | 7         |
| 100 | In-vitro adsorption and sieving coefficient of ticarcillin-clavulanate during continuous haemofiltration. <i>International Journal of Antimicrobial Agents</i> , 2019, 54, 261-264.  | 1.1 | 7         |
| 101 | Pharmacodynamic Evaluation of Plasma and Epithelial Lining Fluid Exposures of Amikacin against <i>Pseudomonas aeruginosa</i> in a Dynamic <i>In Vitro</i> Hollow-Fiber Infection Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .                                     | 1.4 | 7         |
| 102 | Clinically Relevant Epithelial Lining Fluid Concentrations of Meropenem with Ciprofloxacin Provide Synergistic Killing and Resistance Suppression of Hypermutable <i>Pseudomonas aeruginosa</i> in a Dynamic Biofilm Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, . | 1.4 | 7         |
| 103 | Population Pharmacokinetics of Vancomycin in Critically Ill Adult Patients Receiving Extracorporeal Membrane Oxygenation (an ASAP ECMO Study). <i>Antimicrobial Agents and Chemotherapy</i> , 2022, 66, AAC0137721.  | 1.4 | 7         |
| 104 | Evaluation of low-volume plasma sampling for the analysis of meropenem in clinical samples. <i>Analytical and Bioanalytical Chemistry</i> , 2022, 414, 2155-2162.  | 1.9 | 7         |
| 105 | Recovery rates of combination antibiotic therapy using in vitro microdialysis simulating in vivo conditions. <i>Journal of Pharmaceutical Analysis</i> , 2018, 8, 407-412.   | 2.4 | 6         |
| 106 | Population Pharmacokinetics of Periarticular Ketorolac in Adult Patients Undergoing Total Hip or Total Knee Replacement Surgery. <i>Anesthesia and Analgesia</i> , 2019, 129, 701-708.   | 1.1 | 6         |
| 107 | Microsampling to support pharmacokinetic clinical studies in pediatrics. <i>Pediatric Research</i> , 2022, 91, 1557-1561.  | 1.1 | 6         |
| 108 | Oral fosfomycin activity against <i>Klebsiella pneumoniae</i> in a dynamic bladder infection in vitro model. <i>Journal of Antimicrobial Chemotherapy</i> , 2022, 77, 1324-1333.   | 1.3 | 6         |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 109 | The pharmacokinetics of meropenem and piperacillin-tazobactam during sustained low efficiency haemodiafiltration (SLED-HDF). <i>European Journal of Clinical Pharmacology</i> , 2020, 76, 239-247.  | 0.8 | 5         |
| 110 | Pharmacokinetics of fluconazole and ganciclovir as combination antimicrobial chemotherapy on ECMO: a case report. <i>International Journal of Antimicrobial Agents</i> , 2021, 58, 106431.  | 1.1 | 5         |
| 111 | Plasma and Cerebrospinal Fluid Population Pharmacokinetics of Meropenem in Neurocritical Care Patients: a Prospective Two-Center Study. <i>Antimicrobial Agents and Chemotherapy</i> , 2022, 66, .  | 1.4 | 5         |
| 112 | Characterisation of 40â€mg/ml and 100â€mg/ml tobramycin formulations for aerosol therapy with adult mechanical ventilation. <i>Pulmonary Pharmacology and Therapeutics</i> , 2018, 50, 93-99.   | 1.1 | 4         |
| 113 | Pharmacokinetics of Total and Unbound Cefazolin during Venous-Arterial Extracorporeal Membrane Oxygenation: A Case Report. <i>Chemotherapy</i> , 2019, 64, 115-118.   | 0.8 | 4         |
| 114 | Ticarillin and piperacillin adsorption on polyethersulfone haemodiafilter membranes in an ex-vivo circuit. <i>International Journal of Antimicrobial Agents</i> , 2020, 56, 106058.   | 1.1 | 4         |
| 115 | Comparative Plasma Pharmacokinetics of Ceftriaxone and Ertapenem in Normoalbuminemia, Hypoalbuminemia, and Albumin Replacement in a Sheep Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .   | 1.4 | 4         |
| 116 | Prospective Cohort Study of Micafungin Population Pharmacokinetic Analysis in Plasma and Peritoneal Fluid in Septic Patients with Intra-abdominal Infections. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, e0230720.  | 1.4 | 4         |
| 117 | A validated LC-MS/MS method for the simultaneous quantification of the novel combination antibiotic, ceftolozaneâ€tazobactam, in plasma (total and unbound), CSF, urine and renal replacement therapy effluent: application to pilot pharmacokinetic studies. <i>Clinical Chemistry and Laboratory Medicine</i> , 2021, 59, 921-933. | 1.4 | 4         |
| 118 | Effect of Different Piperacillin-Tazobactam Dosage Regimens on Synergy of the Combination with Tobramycin against <i>Pseudomonas aeruginosa</i> for the Pharmacokinetics of Critically Ill Patients in a Dynamic Infection Model. <i>Antibiotics</i> , 2022, 11, 101.   | 1.5 | 4         |
| 119 | Evaluating Mono- and Combination Therapy of Meropenem and Amikacin against <i>Pseudomonas aeruginosa</i> Bacteremia in the Hollow-Fiber Infection Model. <i>Microbiology Spectrum</i> , 2022, 10, e0052522.   | 1.2 | 4         |
| 120 | Plasma and Interstitial Fluid Pharmacokinetics of Prophylactic Cefazolin in Elective Bariatric Surgery Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 0, , .  | 1.4 | 4         |
| 121 | A Loading Micafungin Dose in Critically Ill Patients Undergoing Continuous Venovenous Hemofiltration or Continuous Venovenous Hemodiafiltration: A Population Pharmacokinetic Analysis. <i>Therapeutic Drug Monitoring</i> , 2021, 43, 747-755.   | 1.0 | 3         |
| 122 | Caspofungin Population Pharmacokinetic Analysis in Plasma and Peritoneal Fluid in Septic Patients with Intra-Abdominal Infections: A Prospective Cohort Study. <i>Clinical Pharmacokinetics</i> , 2022, 61, 673-686.  | 1.6 | 3         |
| 123 | Population pharmacokinetics of ciprofloxacin in critically ill patients receiving extracorporeal membrane oxygenation (an ASAP ECMO study). <i>Anaesthesia, Critical Care &amp; Pain Medicine</i> , 2022, , 101080.   | 0.6 | 3         |
| 124 | Pharmacodynamic evaluation of piperacillin/tazobactam versus meropenem against extended-spectrum Î²-lactamase-producing and non-producing <i>Escherichia coli</i> clinical isolates in a hollow-fibre infection model. <i>Journal of Antimicrobial Chemotherapy</i> , 2022, 77, 2448-2455.  | 1.3 | 3         |
| 125 | Propylene Glycol and Glycerol Concentration in Ultrasound Gel. <i>Regional Anesthesia and Pain Medicine</i> , 2013, 38, 75-76.  | 1.1 | 2         |
| 126 | Reply to Rhodes et al. <i>Clinical Infectious Diseases</i> , 2014, 59, 907-908.   | 2.9 | 2         |



| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 127 | Population pharmacokinetics of ticarcillin in critically ill patients receiving extended daily diafiltration. <i>International Journal of Antimicrobial Agents</i> , 2019, 54, 351-355.  | 1.1 | 2         |
| 128 | Low levels of salicylic acid and salicyluric acid are present in synovial fluid of patients taking aspirin at the time of knee arthroplasty surgery. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2020, 47, 1635-1637.   | 0.9 | 2         |
| 129 | Pharmacodynamic Evaluation of a Single Dose versus a 24-Hour Course of Multiple Doses of Cefazolin for Surgical Prophylaxis. <i>Antibiotics</i> , 2021, 10, 602.   | 1.5 | 2         |
| 130 | Development and validation of a UHPLC-MS/MS method to measure cefotaxime and metabolite desacetylcefotaxime in blood plasma: a pilot study suitable for capillary microsampling in critically ill children. <i>Analytical and Bioanalytical Chemistry</i> , 2021, 413, 4483-4491.                  | 1.9 | 2         |
| 131 | Pharmacodynamics of once- versus twice-daily dosing of nebulized amikacin in an in vitro Hollow-Fiber Infection Model against 3 clinical isolates of <i>Pseudomonas aeruginosa</i> . <i>Diagnostic Microbiology and Infectious Disease</i> , 2021, 100, 115329.                                    | 0.8 | 2         |
| 132 | <i>In vitro</i> effect of synovial fluid from patients undergoing arthroplasty surgery on MRSA biofilm formation. <i>Journal of Antimicrobial Chemotherapy</i> , 2022, 77, 1041-1044.  | 1.3 | 2         |
| 133 | A validated UHPLC-MS/MS method for the measurement of riluzole in plasma and myocardial tissue samples. <i>Biomedical Chromatography</i> , 2017, 31, e4030.  | 0.8 | 1         |
| 134 | Pharmacokinetics of Sulfamethoxazole and Trimethoprim During Venovenous Extracorporeal Membrane Oxygenation: A Case Report. <i>Pharmacotherapy</i> , 2020, 40, 713-717.  | 1.2 | 1         |
| 135 | Innovation in microsampling for therapeutic drug monitoring of gentamicin in neonates: a proof-of-concept study. <i>International Journal of Antimicrobial Agents</i> , 2022, 59, 106513.  | 1.1 | 1         |
| 136 | Optimal dosing of cefotaxime and desacetylcefotaxime for critically ill paediatric patients. Can we use microsampling?. <i>Journal of Antimicrobial Chemotherapy</i> , 2022, 77, 2227-2237.  | 1.3 | 1         |
| 137 | Pharmacodynamic evaluation of piperacillin/tazobactam against extended-spectrum $\beta$ -lactamase-producing versus non-producing <i>Escherichia coli</i> in a hollow-fibre infection model. <i>International Journal of Antimicrobial Agents</i> , 2022, , 106623.                                | 1.1 | 1         |
| 138 | Use of the Hollow-Fiber Infection Model to Measure the Effect of Combination Therapy of Septic Shock Exposures of Meropenem and Ciprofloxacin against Intermediate and Resistant <i>Pseudomonas aeruginosa</i> Clinical Isolates. <i>Antimicrobial Agents and Chemotherapy</i> , 2022, , e0214021. | 1.4 | 0         |